YS Biopharma up as its rabies vaccine gets late-stage trial approval in Pakistan

LakeShore Biopharma Co

16/05/2023 14:52

** Shares of drug developer YS Biopharma Co Ltd  YS.O  rise
9.7% to $1.36
    ** Co says its PIKA Rabies Vaccine has received late-stage
clinical trial approval from the Drug Regulatory Authority of
Pakistan
    ** The trial will evaluate the safety and immunogenicity of
co's vaccine in preventing rabies infection
    ** Stock down ~86% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))